: A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997,175(1):16–25.PubMedCrossRef 48. Da Costa XJ, Morrison LA, Knipe DM: Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 2001,288(2):256–263.PubMedCrossRef 49. Bryson Y, Dillon M,

Bernstein DI, Radolf J, Zakowski P, Garratty E: Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993,167(4):942–946.PubMedCrossRef 50. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L: https://www.selleckchem.com/products/sgc-cbp30.html Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992,116(3):197–202.PubMed 51. Looker KJ, Garnett GP: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex ON-01910 concentration Transm Infect 2005,81(2):103–107.PubMedCrossRef 52. Schmidt OW, Fife KH, Corey L: Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis 1984,149(4):645–646.PubMedCrossRef 53. Lakeman AD, Nahmias AJ, Whitley RJ: Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion.

Sex Transm Dis 1986,13(2):61–66.PubMedCrossRef Competing interests The authors declare that they have no competing interests.

Authors’ contributions RB participated in designing the experiments, carried out the animal studies, cell culture work, virus assays, and drafted the manuscript. FY developed the HSV-1 recombinant CJ9-gD, designed the experiments, and participated in their coordination and drafting the manuscript. Both authors read and approved the final manuscript.”
“Background Staphylococcus aureus is a commensal that colonizes the moist squamous epithelium of the human anterior nares. Twenty percent of the population Tolmetin are permanently colonised while the remainder are colonized intermittently [1]. It is an important opportunistic pathogen that can cause superficial skin infections as well as invasive life-threatening conditions such as septic arthritis and endocarditis [2]. The success of S. aureus as a pathogen can in part be attributed to the expression of cell surface protein receptors designated MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) that interact specifically with proteins present in the host plasma and extracellular matrix [3]. MSCRAMMs act as virulence factors that allow S. aureus to adhere to the surface of host cells and to damaged tissue and help it to avoid phagocytosis by neutrophils [4–6] The BMS202 in vitro fibronectin binding proteins (FnBPs) A and B of S. aureus are multifunctional MSCRAMMs which recognise fibronectin, fibrinogen and elastin [7–10].